Paul Hartmann AGSTU:PHH2 +0.49%61 Net Margin % is 3.67% as of Dec. 2025, which is 6% below its 10-year median of 3.92. GuruFocus rates STU:PHH2 with a GF Score™ of 61/100 and a GF Value™ of €229.60 (Fairly Valued). The stock has 4 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Paul Hartmann AG ranks better than 51.41% on this metric.
The historical rank and industry rank for Paul Hartmann AG's Net Margin % or its related term are showing as below:
STU:PHH2'
s Net Margin % Range Over the Past 10 Years
Min: 1.21 Med: 3.92 Max: 4.5
Current: 2.5
STU:PHH2's Net Margin % is ranked better than 51.41% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.09
vs STU:PHH2: 2.50
Paul Hartmann AG (STU:PHH2) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Paul Hartmann AG Net Margin % Related Terms
Paul Hartmann AG Net Margin % Historical Data
* Premium members only.
The historical data trend for Paul Hartmann AG's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:PHH2 vs ISRG, BDX, MDLN: Net Margin % Comparison
For the Medical Instruments & Supplies subindustry, Paul Hartmann AG's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paul Hartmann AG Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Paul Hartmann AG's Net Margin % distribution charts can be found below:
* The bar in red indicates where Paul Hartmann AG's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Paul Hartmann AG (STU:PHH2) has a Net Margin % of 3.67% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Paul Hartmann AG and its competitors. This is near median its historical median of 3.92. Over the past decade, Paul Hartmann AG's Net Margin % has ranged from 1.21 to 4.50. According to the industry distribution chart, Paul Hartmann AG ranks #397 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 48.6%.
Is Paul Hartmann AG's Net Margin % too high?
Paul Hartmann AG's current Net Margin % of 3.67% is near median its 10-year median of 3.92. Over the past 10 years, this metric has ranged from a low of 1.21 to a high of 4.50. The Medical Devices & Instruments industry median Net Margin % is 2.09. Paul Hartmann AG's value of 3.67% is 75.6% above this industry median. Based on the distribution chart, Paul Hartmann AG ranks #397 out of 817 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Paul Hartmann AG has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Paul Hartmann AG's Net Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Paul Hartmann AG ranks #397 out of 817 companies for Net Margin %. This puts Paul Hartmann AG in the upper half of its industry. The industry median Net Margin % is 2.09. Paul Hartmann AG's value of 3.67% is 75.6% above this benchmark. Historically, Paul Hartmann AG's own Net Margin % has ranged from 1.21 to 4.50 over the past decade. While the company's 10-year median is 3.92 vs. the industry median of 2.09, Paul Hartmann AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.09, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Paul Hartmann AG's current Net Margin % of 3.67% is 75.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Paul Hartmann AG and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Paul Hartmann AG's current Net Margin % is 3.67%, which is near median its own 10-year median of 3.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paul Hartmann AG stock overvalued right now?
Based on GuruFocus' analysis, Paul Hartmann AG (STU:PHH2) is currently considered Fairly Valued. The stock's GF Value™ is €229.60, compared to a current price of €205.00 — trading 10.7% below its estimated fair value. The current Net Margin % is 3.67%, which is near median its 10-year median of 3.92 and 75.6% above the Medical Devices & Instruments industry median of 2.09. Paul Hartmann AG's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Paul Hartmann AG (STU:PHH2), the current Net Margin % is 3.67% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Paul Hartmann AG (STU:PHH2) Overvalued in 2026?
Based on GuruFocus' analysis, Paul Hartmann AG stock appears to be undervalued.
The current stock price of €205.00 is trading 10.7% below its estimated GF Value™ of €229.60.
GuruFocus considers Paul Hartmann AG to be Fairly Valued.
Key valuation signals for STU:PHH2:
Net Margin %: 3.67% (near median its 10-year median of 3.92)
GF Value™: €229.60 vs. price of €205.00 (10.7% below fair value)
Industry Position: 75.6% above the Medical Devices & Instruments median (#397 of 817)
No single metric tells the full story. See the STU:PHH2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Paul Hartmann AG engages in the production of medical and hygiene products. It operates through Wound Management, Incontinence Management and Infection Management and other segments. The Wound segment comprises wound dressing and treatment, compression therapy, first aid, immobilization, and diagnostics. The Incontinence segment provides incontinence hygiene, patient care, and medical skin care. The Infection segment consists of custom procedure trays, surgical draping systems, disposable surgical instruments, and disinfectants. The Other activities include activities in cotton-wool products, medical consumer goods and pharmaceutical products and others. All the activities are functioned through the region of US and derive revenue through the sale of medical and hygiene products.
61GF Score
Get the complete analysis for STU:PHH2
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:PHH2 has been successfully added to your 
